MRA Group’s Post

📊 In the age of huge data sets, AI and innovative chemistry, how do you decide which molecules from your vast libraries have potential early on? 🔬When cell culture doesn’t provide the context of a complex biological system and organoids aren’t scalable enough, how do you bridge the gap between in vitro and mammals? 💡What if you could screen hundreds of thousands of compounds in vivo within weeks for a few £s per compound? 📍Come and visit our booth in the breakthrough zone - BZ10 - to find out more #elrig #elrigdd24 #drugdiscovery #HTS

Join Blake Mandell from Transcend Therapeutics at the upcoming Fierce Biotech Summit on Sept 30 - Oct 1 in Boston as he shares his expertise in groundbreaking biotech innovations and advancements. Register now and save up to $500 with the Early Bird Rate: https://ow.ly/uTAE50SyYgy Learn, Network and Connect over two jam-packed days with 500+ industry leaders and gain valuable insights into the future landscape of biotech. Stay Updated on all our events by following Fierce Life Sciences Events #FierceBiotechSummit #WeAreFierce #FierceBiotech #FierceBiotechSummit #BiotechInnovation #LifeSciences #PharmaIndustry #BiotechLeaders #Biotech2024 #BiotechTrends

More #Biotech news today in the neuropsychiatry space: a new company, Neurosterix, emerging with an impressive portfolio of allosteric modulators for certain neurological conditions. Their leading asset is reported to be a selective muscarinic M4 PAM (Positive Allosteric Modulator), in the preclinical stage, as a potential treatment for Schizophrenia. Strategic Landscape Insights: The wave of these relatively newer MOAs to treat Schizophrenia may differentiate, but others (Cerevel Therapeutics; Karuna Therapeutics/ now Bristol Myers Squibb) also have their treatment candidates in play. For certain 'underserved' neuro-conditions, unmet needs exist. The MOA of these allosteric modulators is described as "binding to target receptors outside of active sites, where the natural ligand and traditional drugs operate." This non-competing mechanism allows for "greater selectivity and more precision over the control of biological pathways, potentially delivering improved efficacy and safety." #Biotech #Innovation #Neuropsychiatry #Neuroscience #Healthcare Quotes on MOA from Yahoo Finance via Addex Therapeutics news release.

A tale of perseverance and strategy at 2seventy bio. In just two years, the biotech has weathered layoffs, pipeline reorganizations, fierce competition, FDA safety warnings, and discontinued clinical trials. Yet, CEO Chip Baird credits transparency and a committed staff for keeping the company afloat. Despite the challenges, 2seventy is now on the path to profitability, with Baird predicting reaching that milestone next year. Stay tuned for potential growth strategies once breakeven is achieved. #biotech #perseverance #strategy #celltherapy #CarT #multiplemyeloma #advancedtherapies #regenerativemedicine #lifescience #lifesciences #biotech #biotechnology bluebird bio #milestones #profitability

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Allogene's $110M offering; Apellis refinances: Plus, news about FogPharma, Artbio, Enveric, MindBio and Allozymes: Allogene taps investors for $110M: The biotech priced a common stock offering that included mutual funds, institutional investors and healthcare specialists. Some board members and executives also took part in the financing. The Bay Area biotech now has rights in the EU and UK for the allogeneic cell therapy called cemacabtagene ansegedleucel. — Kyle LaHucik Apellis refinances: The commercial-stage biotech received about $375 million in a credit facility from investment firm Sixth Street. About $326 million went to buy out a development liability with SFJ Pharmaceuticals, and the net proceeds were about $32 million. — Kyle LaHucik FogPharma teams up with Artbio: The biotechs plan to co-develop 212Pb alpha radioligand therapies and will “contribute equally” across R&D and commercialization. No financials were disclosed. Both startups have raised large financing rounds in the past six months. — Kyle LaHucik Enveric, MindBio sign term sheet partnership: Enveric is out-licensing one of its “novel psilocin prodrug” programs to MindBio. If the companies opt to sign into a “definitive agreement,” MindBio could receive up to $66.5 million in upfront and milestone payments, as well as royalties ranging from 2.5% to 10% on all future sales. — Max Gelman Allozymes raises $15M Series A: The Singapore-based company plans to use the money to expand to Europe and find new partners in both the food and pharma industries. Allozymes said it has capabilities in enzyme screening, sorting and detection that use AI and machine learning algorithms. — Max Gelman #lucidquest #genetherapy #celltherapy

Gene&Cell Therapy >> Allogene's $110M offering; Apellis refinances: Plus, news about FogPharma, Artbio, Enveric, MindBio and Allozymes: Allogene taps investors for $110M: The biotech priced a common stock offering that included mutual funds, institutional investors and healthcare specialists. Some board members and executives also took part in the financing. The Bay Area biotech now has rights in the EU and UK for the allogeneic cell therapy called cemacabtagene ansegedleucel. — Kyle LaHucik Apellis refinances: The commercial-stage biotech received about $375 million in a credit facility from investment firm Sixth Street. About $326 million went to buy out a development liability with SFJ Pharmaceuticals, and the net proceeds were about $32 million. — Kyle LaHucik FogPharma teams up with Artbio: The biotechs plan to co-develop 212Pb alpha radioligand therapies and will “contribute equally” across R&D and commercialization. No financials were disclosed. Both startups have raised large financing rounds in the past six months. — Kyle LaHucik Enveric, MindBio sign term sheet partnership: Enveric is out-licensing one of its “novel psilocin prodrug” programs to MindBio. If the companies opt to sign into a “definitive agreement,” MindBio could receive up to $66.5 million in upfront and milestone payments, as well as royalties ranging from 2.5% to 10% on all future sales. — Max Gelman Allozymes raises $15M Series A: The Singapore-based company plans to use the money to expand to Europe and find new partners in both the food and pharma industries. Allozymes said it has capabilities in enzyme screening, sorting and detection that use AI and machine learning algorithms. — Max Gelman #lucidquest #genetherapy #celltherapy

Last week the Olaris team met for a company off-site where Liz debuted an incredible and 'vivid' vision of where Olaris is heading. On the road ahead: groundbreaking products that transform every step of the transplant process (organ donation, EVMP, living with a transplant), world-class services, software that democratizes metabolomics, deep and trusted partnerships with academia and biopharma, rigorous training, career development opportunities with a "dream coach," and patient partners providing input at every stage of what we do - oh and there may even be some pumpkin spice lattes! #team #dreamteam #vividvision #goals #metabolitestransformingmedicine #biotech #diagnostics #metabolites

𝐈𝐃𝐑𝐱'𝐬 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐢𝐨𝐧 𝐨𝐟 𝐚𝐧 𝐨𝐯𝐞𝐫𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞𝐝 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐧𝐠 IDRx has announced the successful completion of an oversubscribed $120M Series B financing, led by RA Capital Management, Commodore Capital, and Blackstone Multi-Asset Investing. The funds will support the ongoing Phase 1/1b StrateGIST 1 study of IDRx's lead candidate, IDRX-42. Key highlights: • Fast Track designation granted by the U.S. FDA for IDRX-42. • Promising preliminary Phase 1 data, showing a 43% ORR in second-line GIST patients. • Strong backing from top-tier investors, including RA Capital, Andreessen Horowitz, and Merck KGaA. This milestone brings IDRx closer to its goal of transforming GIST treatment with precision therapies designed to address treatment resistance and adverse events. The company expresses its gratitude to the dedicated team, partners, and investors who continue to support its mission to elevate the standard of care for GIST patients. #Biotech #PrecisionMedicine #Oncology #GIST #ClinicalTrials 

Meet our founders! 1cBio was founded in 2022 by Jit Chakravarty, Sunny Chen, and Son Pham. Their collaborative journey began almost a decade ago at Medivation, where Jit played a key role in the development and approval of XTANDI® (enzalutamide), while Sunny was part of the team that helped develop TALZENNA®️ (talazoparib). SPARCBIO emerged following Pfizer’s acquisition of Medivation, and as co-workers evolved into first-time entrepreneurs, they fostered a collective synergy in their ability to transform inventions into innovations and build companies with sustainable portfolios. Through countless late-night conference calls, working dinners, and long flights, Jit, Sunny, Son, and their dedicated team developed and supported five unique small-molecule programs. Their efforts resulted in four clinical candidates between 2016 and 2022. In 2019, SPARCBIO's assets were sold in a transaction involving cash and stock, laying the foundation for a new public company (NYSE: NUVB). With an amalgamation of experiences, both personal and professional, the team at 1cBio is driven by their common desire to positively impact patients' lives. These efforts continue to propel the company forward as a clinical-stage enterprise. To learn more visit: www.1cbio.com #FoundingStory #1cBio #Our1cause #DrugDiscovery #DrugDevelopment #BioPharma #Oncology #RareDisease #HPP

A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications. Despite the significant need for rare disease therapies, investment remains low due to the small prevalence of these conditions. Companies like Ultragenyx and Zevra Therapeutics have developed creative funding models, including royalty financing and equity, to support their research. To make an impact, however, more funding and regulatory initiatives are needed to address the extensive need for rare disease treatments. https://lnkd.in/eY9cfZyv #raredisease #biotechfunding #investment #biotechnology